These 146 drug hospitals in Shaanxi are not for sale.

According to the announcement, from 0:00 on December 10, 2019, all kinds of public medical institutions at all levels in Shaanxi Province, voluntary participation in the pilot expansion of the military medical institutions in Shaanxi and medical insurance fixed-point social medical institutions (all do not include the pilot city of Xi'an), according to the 4 plus 7 expansion of the selected prices for procurement and salesselected non-supply Shaanxi varieties, can be selected in Shaanxi supplyaccording to the announcement, the alliance area (non-Shanxi) drug centralized procurement of selected varieties, Xi'an City 4 and 7 city drug centralized procurement of selected varieties, confirm the supply of Shaanxi at the selected price at the winning price of the network procurement at the selected price;Seiber Blue interpretation:4 plus 7 expansion of the varieties of non-supply Shaanxi, can also be purchased in ShaanxiIf the winning products of Shaanxi are not supplied to confirm the supply of Shaanxi according to their own winning price, it can be purchased on the grid at the same time with the supply of Shaanxi, and if not confirmed, it can be directly linked to the network and the medical institutions to negotiate directlyHowever, this is not clear, non-supply Shaanxi products in Shaanxi procurement, is to divide the share of the band procurement, or share the residual share of the band procurement, which needs to continue to studythere is also a problem, is that there are many non-supply Shaanxi's selected products, of which the price is higher than the supply of Shaanxi selected productsFor example, Ruishuvasttin tablets 10mg x 14, the price of the supply of Shaanxi is 4.18 yuan, but the non-supply Shaanxi's winning price is 5.6 yuan and 6.84 yuanLike this situation, if non-supply Shaanxi products in Shaanxi according to the price of the purchase of the net, pharmaceutical companies and medical institutions will be balanced?the non-selected varieties, to reduce the priceaccording to the announcement, the evaluation of unselected varieties to be purchased in Shaanxi, need to meet the following conditions:1, the enterprise reported prices or confirmed prices below or equal to "Xi'an City 4 plus 7 city drug centralized procurement price" and not higher than "Shanghai 4 plus 7 city drug centralized procurement full-caliber red price" to give the price limitMedical institutions and linked-up enterprises may negotiate their own prices, below or equal to this price procurement2, no "Xi'an City 4 plus 7 city drug centralized procurement price" and "Shanghai 4 plus 7 city drug centralized procurement of full-caliber red price", to be directly linked to the netThe purchase shall be independently negotiated by medical institutions and the online enterprises3, the enterprise reported the price is higher or not confirmed "Xi'an City 4 plus 7 city drug centralized purchase price" and "Shanghai 4 plus 7 city drug centralized procurement of full-caliber red price" products, the withdrawal of the networkSeiber Blue interpretation:is different from the previous 4 plus 7 band volume procurement, Shaanxi 4 plus 7 expansion of the price requirements have two red lines: 1, "Xi'an City 4 plus 7 city drug centralized procurement price"; These two red lines and the price of the expansion of the 4 plus 7, there is still a certain advantageBut there is no denying that the price of drugs fell again and again, has been unstoppableIf the price reduction and the purchase volume is proportional, the pharmaceutical companies need to consider, is whether the enterprise itself can withstand the pressure of price exchangehas not been evaluated varieties, facing the elimination crisis
according to the announcement, for the over-rated varieties to be purchased in Shaanxi, need to meet the following conditions:with the common name of the same dosage type of products, through consistency evaluation products hanging net less than three, the enterprise reported the price or confirmed price is lower than or equal to the alliance area (Shanxi) drug centralized procurement of selected varieties price or difference ratio calculation price, to be pricedMedical institutions and linked-up enterprises may negotiate their own prices, below or equal to this price procurementif the following, will face being removed from the net:1, with the common name of the same specifications of products, through the consistency evaluation of products have reached three or more, not through the consistency evaluation of the product to withdraw the network2, if the price quoted by the enterprise is higher than the price of the selected varieties selected in the centralized procurement of drugs in the Alliance Region (Shanxi) or if the price is calculated or the price is not confirmed, the hanging network shall be withdrawnlook at the above announcement and can see that 146 drugs have been removed from the internet, as detailed at the end of the articleCypress Blue Review:According to the Opinions on The Conformity Evaluation of Quality and Efficacy of Generic Drugs issued by the General Office of the State Council on March 5, 2016(State Office issued (2016) No8), it is clearly required that the production enterprises with the same varieties of drugs through consistent evaluation reach more than 3, and no longer select varieties that have not passed the consistent evaluation in the areas of centralized procurement of drugsmeans that once the consistency evaluation of this variety has reached three pharmaceutical companies, the varieties that have not passed the consistency evaluation will face the loss of the hospital market according to the requirements of the State Drug Administration, the new registration classification of chemical drugs approved before the implementation of the list of generic drugs including essential drug varieties, since the first varieties through the consistency evaluation, other pharmaceutical production enterprises of the same varieties in principle should be completed within 3 years of consistency evaluation with more and more varieties through consistency evaluation, the first three-year period after the evaluation, for many pharmaceutical companies, is the pressure, but also the driving force of continuous progress with the introduction of generic drug consistency evaluation policy and document intensive, as well as the promotion of national band procurement, many pharmaceutical companies have also realized that the consistency evaluation of generic drugs is the general trend, not only to do, but also to do it early attached: Shaanxi cancels the list of drugs on the internet original title: 146 drugs, hospitals do not sell